Navigation Links
Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
Date:9/5/2007

a's lead anticancer drug, is a novel targeted therapy that blocks the production of Bcl-2, a protein that appears to be a fundamental cause of cancer treatment resistance. By knocking down Bcl-2, Genasense may enhance the effectiveness of chemotherapy in patients with advanced melanoma. Genasense in melanoma has Orphan Drug designations in Australia and the U.S., along with Fast Track designation in the U.S.

In its initial Phase 3 trial, Genta performed the largest randomized controlled trial that has ever been conducted in patients with advanced melanoma. In that trial, 771 patients were randomly assigned to receive chemotherapy with DTIC alone or in combination with Genasense. A scientific article that describes efficacy and safety results from this study can be accessed at: http://www.jco.org/cgi/content/abstract/JCO.2006.06.0483v1.

In that trial, patients were prospectively stratified according to levels of a blood enzyme known as LDH. Further analysis of this study showed that maximum benefit accrued to patients whose LDH biomarker did not exceed 80% of the upper limit of normal. Efficacy results in this group of 274 patients, which are the focus of the confirmatory AGENDA trial, are displayed in the table below. (The hazard ratios indicate that the addition of Genasense to DTIC was associated with a 42% reduction in the risk of disease progression and a 36% reduction in risk of death.)

Endpoint Genasense/DTIC DTIC Hazard P

Ratio

Overall response 20.8 % 7.2 % 0.002

Durable response 10.7 % 2.4 % 0.007

Progression-free survival,

median 3.6 mos. 1.6 mos. 0.58 <0.0001

Overall survival, median 12.3 mos. 9.9 mos. 0.64 0.0009

A
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
2. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
3. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
4. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
5. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
6. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
7. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
8. Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... 2015 China,s startup ... Patch, a wearable medical device that can continuously monitor ... providing safety guidance for pregnant women. The device will ... device, which measures 4 centimeters in diameter, is as ... more than an Apple earphone cord. The small and ...
(Date:9/3/2015)... , Sept. 3, 2015 HeartWare ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that its President and Chief Executive Officer, ... 2015 Wells Fargo Healthcare Conference at 8:50 a.m. ET ... Sept. 9-10, 2015 at The Hyatt Regency, ...
(Date:9/3/2015)...  The findings of a year-long investigation conducted by ... company,s handling of its Recovery IVC filter product ... , part one of the series revealed ... 27 fatalities, have been associated with the Recovery device. ... C.R. Bard in 2004 which linked the Recovery IVC ...
Breaking Medicine Technology:Modoo to Debut at Kickstarter: First Device on the Market that Enables Continuous Monitoring of Fetal Heart Rate and Fetal Movement 2HeartWare Presentation At The 2015 Wells Fargo Healthcare Conference To Be Webcast 2IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 2IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 3
... just 21 days, CVS/pharmacy,s ninth annual in-store fundraising campaign to ... $4.1 million. The funds raised by the campaign will be ... the funding of new clinical research aimed at developing new ... of finding a cure for ALS. This donation brings the ...
... Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical ... for the treatment of human viral diseases, today announced ... the 61st Annual Meeting of the American Association for ... 2010 in Boston, Massachusetts). The abstracts being presented are ...
Cached Medicine Technology:ALS Research Gets a $4.1 Million Boost from CVS/pharmacy Fundraising Campaign 2ALS Research Gets a $4.1 Million Boost from CVS/pharmacy Fundraising Campaign 3Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 3
(Date:9/3/2015)... Lawrenceville, Georgia (PRWEB) , ... September 03, 2015 ... ... the spread of disease in Haiti, has partnered with Slingshot® Product Development Group ... no electricity or running water. Michael Wahl with DriButts plans to bring 600 ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... Spouse/Caregiver Scholarship applications are open for spring 2016. Scholarships are awarded two times ... Hope For The Warriors® is a national nonprofit dedicated to restoring a sense ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... the release of her debut book, “Stop Wasting Your Time Blaming Others for ... (September 6), Hartley’s guide to overcoming life’s obstacles by taking full responsibility for ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... leading provider of comprehensive eating disorder treatment for adults and adolescents struggling ... Ileana Calinoiu, MD has joined the medical treatment team. As a Staff ...
(Date:9/3/2015)... ... September 03, 2015 , ... As a result ... fully insured employer-sponsored health insurance plans, more employers are moving to a self-funded ... released from the 2014 United Benefit Advisors (UBA) Health Plan Survey. , UBA’s ...
Breaking Medicine News(10 mins):Health News:DriButts Diapers Rely on Slingshot Help in Haiti 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 3Health News:Hope For The Warriors Spouse/Caregiver Scholarships Now Open for Spring 2016 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 2Health News:Popular Advice Columnist Shares Her Path to Overcoming Personal Trials in Debut Book 3Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4
... more than two hours per week reduces the risk of ... compared to women of the same race who do not ... Results were presented at the Third AACR Conference on ... Oct. 3, 2010. "People often want to ...
... over-activation of a single protein may shut down the ... common form of Parkinson,s disease. The finding of this ... already known to inhibit it, thus controlling symptoms of ... Previous research demonstrated that a protein called ...
... program designed to achieve and maintain weight loss improves ... and obese individuals with type 2 diabetes, according to ... the National Institutes of Health and the Centers for ... the Sept. 27, 2010, issue of the Archives ...
... instrument due to fly aboard NASA,s James Webb Space Telescope ... facilities at the Rutherford Appleton Laboratory (RAL) in the United ... to areas of investigation as diverse as the first light ... other stars. "The start of space simulation testing ...
... October 1, 2010 A newly published study in ... the American Dental Association (JADA), conducted at New ... efficacy of a new novel method for controlling xerostomia, ... study concludes that use of a unique mucoadhesive patch, ...
... Boston Medical Center (BMC) researchers have each been awarded ... Alternative Medicine (NCCAM) to study the effectiveness of integrative ... MD, MPH, attending physician in the department of family ... to investigate the use of Herbs and non-vitamin Dietary ...
Cached Medicine News:Health News:Vigorous exercise reduces breast cancer risk in African-American women 2Health News:Parkinson's disease: Excess of special protein identified as key to symptoms and possible new target for treatment with widely used anti-cancer drug imatinib 2Health News:Parkinson's disease: Excess of special protein identified as key to symptoms and possible new target for treatment with widely used anti-cancer drug imatinib 3Health News:Lifestyle intervention improves risk factors in type 2 diabetes 2Health News:Lifestyle intervention improves risk factors in type 2 diabetes 3Health News:NASA's Webb telescope MIRI instrument takes one step closer to space 2Health News:NASA's Webb telescope MIRI instrument takes one step closer to space 3Health News:NASA's Webb telescope MIRI instrument takes one step closer to space 4Health News:New approach for treating dry mouth presented in study published in October 2010 issue of JADA 2Health News:New approach for treating dry mouth presented in study published in October 2010 issue of JADA 3Health News:Boston Medical Center receives 2 grants for integrative medicine research 2
The Acute Care myoglobin method is an in vitro diagnostic test for the measurement of myoglobin in heparinized whole blood /plasma. Myoglobin measurements can be used as an aid in diagnosing myocardi...
... cardiac markers are available on ... Cardiac Troponin I (cTnI) is ... sensitivity and specificity for myocardial ... soon following AMI. CK-MB (mass) ...
... For the quantitative determination of myoglobin concentration ... ELISA test is based on the principle ... The assay system utilizes a unique monoclonal ... on the myoglobin molecule. Mouse monoclonal anti-myoglobin ...
Prolactin Radioimmunoassay...
Medicine Products: